September 13, 2022
Vyriad, Inc. Appoints Scott Beck as Chief Operating Officer
A seasoned executive with deep knowledge and experience of biotechnology and healthcare operations.
May 17, 2022
Vyriad, Inc. Raises $29.5M in Series B Funding Led by Renowned Genetics Entrepreneur
Vyriad, Inc. today announced $29.5M in new funding led by Mr. Harry Stine of Stine Seed Farms, LLC with participation from existing investors. Stine Seed Farms joins Mayo Clinic, Mirae Asset, Regeneron Pharmaceuticals Inc., Southeast Minnesota Capital Fund (SMCF), and several high-net-worth individuals on the Vyriad investment roster.
April 7, 2022
Vyriad creates potential oral covid vaccine
An interview with Dr. Stephen Russell discussing the development of an oral vaccine from Vyriad.
April 5, 2022
Oral Vaccine Boosts COVID Immunity
Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced results confirming the activity of an oral vaccine formulation for boosting immunity against SARS-CoV-2.
August 24, 2021
Vyriad, Inc. Appoints Harry Hoffman to its Board of Directors
Harry is a highly regarded Life Sciences Investor, previously served as CIO and Treasurer to Mayo Clinic.
May 9, 2021
How Safe are Staff and Patients in a Vaccinated World?
Measuring COVID-19 antibodies with a high-throughput clinical assay
February 23, 2021
Imanis Life Sciences Announces New Data from Clinical Assay Measuring SARS-CoV-2 Neutralizing Antibodies
Clinical validation of high throughput assay that provides numeric results (titer) of neutralizing antibodies. Former COVID-19 patients, in a small preliminary sample set, saw marked decline in neutralizing antibodies within six months. Assay shows no guarantee that severe disease results in higher levels of antibody protection.
December 1, 2020
Vyriad Expands Clinical Study of Oncolytic Virus Therapy in Bladder Cancer PatientsRead more
November 19, 2020
Imanis Life Sciences Announces Improvements and Increased Capacity of IMMUNO-COV™️, a First-in-Class Neutralizing Antibody Test for COVID-19
High-throughput clinical assay detects and quantifies SARS-CoV-2 neutralizing antibodies
September 14, 2020
Imanis Life Sciences to Present IMMUNO-COV, a First-in-Class Neutralizing Antibody Test for COVID-19, at American Society of Gene and Cell Therapy Symposium
High-throughput clinical assay detects, quantifies SARS-CoV-2-neutralizing antibodies. Imanis Life Sciences is an affiliate of Vyriad Inc.
July 20, 2020
Vyriad Announces Initiation of Phase 2 Trial in Multiple Cancer Indications
Study combines Vyriad’s oncolytic virus Voyager-V1 and the PD-1 inhibitor Libtayo® (cemiplimab) in skin, lung, liver and uterine cancer
May 29, 2020
Vyriad Inc. to Present Clinical Trial Updates for its Oncolytic Virotherapies at Virtual 2020 ASCO Annual MeetingRead more
May 28, 2020
Scientific Paper Available on Development and Validation of IMMUNO-COV™, Vyriad’s SARS-CoV-2 Virus-Neutralizing Antibody TestRead more
May 12, 2020
Vyriad Inc. Announces Development of a New Antibody Test to Determine Protective Immunity From COVID-19Read more
April 28, 2020
Vyriad Oncolytic Measles Virus Therapy Enhances T-cell Responses in Multiple Myeloma PatientsRead more
December 11, 2019
Vyriad Inc. Names Experienced Life Sciences Investors Edwin Kania and Nathan Stacy to its Board of DirectorsRead more
November 6, 2019
Regeneron and Vyriad Announce Strategic Agreement for Discovery and Development of New Oncolytic Virus Treatments for Cancer
Phase 2 trial will evaluate combination of PD-1 inhibitor Libtayo® (cemiplimab-rwlc) and oncolytic virus Voyager-V1; preclinical research collaboration will explore new oncolytic virus treatments. Vyriad to receive upfront payment and equity investment from Regeneron.
July 28, 2018
Vyriad Announces Collaboration with Merck KGaA and Pfizer to Evaluate Oncolytic Virus, Voyager-V1, in Combination with Anti-PD-L1 Antibody, Avelumab, in Phase 1 Clinical Study for Metastatic Colorectal CancerRead more
May 10, 2018
Vyriad to Build State-of-the-Art Facility for Manufacturing Oncolytic Virus Anti-Cancer Vaccines in Rochester, Minn.
Custom buildout to be financed by recently completed $9 million secured convertible note funding
August 15, 2017
Clinical trial uses a genetically engineered virus to fight cancer
Sanford Health first in nation to launch Phase I of the Vyriad viro-immunotherapy trial
April 25, 2017
Tessa Therapeutics and Vyriad Form Partnership to Create Next Generation of Cancer Immunotherapy Treatments
Combination of Tessa’s Virus Specific T cell (VST) platform and Vyriad’s oncolytic viruses are highly synergistic and have the potential to effectively target a broad range of hard-to-treat solid tumors
August 16, 2016
Vyriad Announces Agreement with Imanis Life Sciences for Development of Theranostic Tests to Predict Responsiveness to Oncolytic VirotherapyRead more
August 5, 2016
Vyriad Appoints Alice Bexon, MD, as Chief Medical Officer
Bexon Clinical Consulting to provide Vyriad with clinical operations support
August 5, 2016
Vyriad Signs Exclusive License Agreement for STING Technology for Development of Enhanced Oncolytic Virotherapy Treatments
Company secures equity position in StingInn, LLC
March 18, 2016